Loomis Sayles & Co. L P Sells 9,111 Shares of Jazz Pharmaceuticals PLC $JAZZ

Loomis Sayles & Co. L P lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 134,557 shares of the specialty pharmaceutical company’s stock after selling 9,111 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Jazz Pharmaceuticals were worth $14,279,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of JAZZ. SVB Wealth LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth $36,000. Hantz Financial Services Inc. increased its stake in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the period. Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the last quarter. Brooklyn Investment Group lifted its stake in shares of Jazz Pharmaceuticals by 411.1% during the first quarter. Brooklyn Investment Group now owns 552 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 444 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $80,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 18,000 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $181.09, for a total value of $3,259,620.00. Following the completion of the sale, the director owned 390,826 shares of the company’s stock, valued at $70,774,680.34. This trade represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 50,893 shares of company stock worth $8,559,699 over the last ninety days. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ JAZZ opened at $176.61 on Monday. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock has a market cap of $10.73 billion, a P/E ratio of -26.24, a P/E/G ratio of 8.49 and a beta of 0.29. The firm has a 50 day moving average price of $143.87 and a 200 day moving average price of $125.27.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Bank of America boosted their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. Finally, The Goldman Sachs Group upped their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $195.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.